Thank you for submitting your manuscript for consideration by the EMBO Journal. We have now received a full set of referee reports on your manuscript, which are included below for your information.
expect a higher abundance of VEGFR-3 than VEGFR-2. If that was so, was there enough VEGFR-2 for a meaningful analysis of PLA sites to be done? Figure 8F are not convincing. The images only show a small amount of each blot so it is hard to assess the specificity of the results. The Authors should provide the journal with images of the entire blots to demonstrate specificity.
The Western blots in
Referee #3:
Comments for Editors
Thank you for giving me the opportunity to review this manuscript. This study by Urner et al. attempts to demonstrate the role of ILK as a regulator of VEGFR3 signaling and lymphatic vascular growth. The authors describe the phenotype of ILK-knockout embryos by endothelial-specific depletion of ILK and show that they exhibit enlarged jugular lymph sac, edema, and lethality. The authors also claim that lymphangiogenesis is increased in adult cornea and post-myocardial infarction (MI) myocardium after lymphatic ILK deletion, and that ILK impedes the interactions between VEGFR3 and β1 integrin. Although some mechanisms are proposed with in vivo and in vitro experiments, they are superficial and their causative involvements in in vivo phenotype of endothelial ILK-knockout embryos remain unclear, which makes this paper insufficient to reach the conclusions. Therefore, I would like to suggest this manuscript to be rejected unless all the comments are appropriately addressed.
Comments for the authors
The authors demonstrates the role of ILK in lymphatic vessel by showing that ILK inhibits the interaction between β1 integrin and VEGFR3 signaling, thereby negatively regulating lymphangiogenesis. The authors described the phenotypes in ILK-knockout embryos and the cell autonomous function of ILK as a regulator of lymphangiogenesis after myocardial infarction and in cornea by inhibiting the interaction between VEGFR3 and β1 integrin, which they claim is modulated by mechanical stimulation. However, the underlying mechanisms are not comprehensively investigated in vivo and in vitro. Furthermore, some of the presented data are insufficient to reach the conclusions.
Major comments: 1. In Figure1, the authors claim that ILK prevents lymphatic overgrowth during mouse development as evidenced by the phenotype of endothelial ILK-knockout (KO) embryo, a model established by using the Flk1-Cre mice, which had enlarged jugular lymph sac (JLS) and increased lymphatic endothelial cell (LEC) number. The major concern is that Flk1-Cre mice might affect the developing blood vessels of major organs such as brain, heart, and kidney, all of which can be a cause of edema other than the defects in lymphatic morphogenesis. The authors used Prox1-CreERT2 mice to specifically delete ILK in adult period. It is questionable why the authors did not use this Cre line for the developmental analysis in Figures 1-4 . Furthermore, the authors showed gross embryonic day 13.5 image with head bleeding in Figure 1E by endothelial ILK-KO, which is quite an unusual phenotype to occur by lymphatic-specific defect. This should be explained and discussed in more detail.
2. The authors showed the increase in Ilk gene expression during mouse embryonic development (E12.0-E13.5) and their inverse correlation with pHH3+ LECs and VEGFR3/phospho-tyrosine sites in Figure EV2 . However, staining and expression patterns of ILK 'protein' in mouse embryo samples should be provided to see if they are expressed in lymphatic vessels and in blood vessels during development in addition to adult lymphatics which the authors have already described (ear skin and post-MI heart lymphatics).
3. In Figure 5 , the authors claim that lymphatic ILK-KO in adult period increases lymphatic vessel density (LVD) in mouse ear skin. The authors should present a lower magnification image to show that the LVD is indeed increased in ILK-KO. Furthermore, lymphatic vessel morphology in control ear skin ( Figure 5B ) seems quite strange because VEGFR3 expression seems heterogeneous compared to ILK-KO; we suggest evaluating images of similar areas of ear skin between control and ILK-KO. In addition, in Figure 5E -F, when normalized by vessel 'diameter', pHH3+ LECs seem similar between control and ILK-KO; this should also be compared in similar areas of ear skin.
Minor comments: 1. The authors claim that adult ILK-KO in mouse heart does not bring any changes in LVD in physiologic conditions, but LVD is increased after MI. However, ILK is known to be expressed in cardiomyocytes and regulate cardiac function as the authors mentioned, but its role is unknown in the cardiac lymphatics. The authors should also check the protein expression patterns of ILK in cardiac lymphatics. Furthermore, post-MI hearts in ILK-KO mice seem to have not only increased LVD but also increased blood vessel density in Figure 6F -6G, which suggests that ILK-KO itself might not be the contributing factor of increased LVD in post-MI hearts.
2. The authors claim that ILK does not regulate β1 integrin activation in LECs by providing activated β1 integrin staining in Figure 3A -D. However, it is hard to reach such conclusion with this data alone. As shown in Figure EV2 , changes in transcript levels of β1 integrin according to ILK might be necessary to support the authors' claim. In addition, β1 integrin is quite non-specific and binds to any receptors. Is there any specific subtype of alpha family integrin as a partner for VEGFR3 and ILK interaction in LECs?
3. In Figure 4 , the authors claim that LEC proliferation by ILK-KO is rescued by heterozygous deletion of β1 integrin in endothelial cells during mouse development by analyzing parameters such as pHH3 and p-Tyr PLA staining. However, the gross phenotype in Figure 4C looks worse than the ILK-KO phenotype alone in terms of overall embryo size at E13.5 and hemorrhage, which should be discussed by the authors. 4 . LEC numbers seem similar between the control and ILK-KO but the Lyve-1 staining pattern seems different between the control and ILK-KO groups because it seems decreased in the ILK-KO group ( Figure 2C as well as in Figures 3A and 3C ), which is inconsistent with the authors' claim.
5. According to the authors' claim, ILK-KO consistently increases LVD, even 3 weeks after Cre induction. It is questionable whether p-VEGFR3 remains much higher than the control even 3 weeks after the Cre induction in Figure 5H . Have the authors observed changes in LVD for longer than 3 weeks after Cre induction? 6. It is interesting that the corneal lymphatic sprouts are frequently observed after lymphatic ILK-KO in Figures 5I-J without any stimulating factors such as VEGF-C. Is the same phenomenon also observed in other important lymphatic vasculatures such as trachea and lymph node? If the adult ILK-KO mice show this aberrant lymphangiogenic response, does this mice survive okay? Do these mice have lymphedema features, since the authors mentioned in Figure 8 that mechanical stimuli (such as increased fluid accumulation) reduces ILK and facilitates VEGFR3 phosphorylation? What happens in later periods of lymphatic development such as in E14.5-16.5 skin dermis by ILK knockout?
7. Authors show that mechanical stress reduces ILK and increases the interaction between the β1 integrin and VEGFR3 by in vitro studies in Figure 8 . However, in the cornea model the authors showed in Figures 5I-J , what is the possible upstream that depletes ILK in the aspect of pathologic settings, because the authors did not manipulate any mechanical stimuli in the adult cornea with or without ILK.
8. To convincingly demonstrate the differences in JLS by ILK-KO, the authors should describe which region of embryos, i.e. spanning from neck to heart, were sectioned for analysis for Figure 1 in Material and Methods section. Point-by-point reply to the referees' comments:
We would like to thank the referees for their advice that helped to strengthen our manuscript. Here we explain how we carefully followed the referees' suggestions.
Referee #1:
The manuscript by Urner and colleagues describes the phenotype of lymphatic vessels devoid of Integrin-linked kinase, both in developing and adult mice. The authors report that ILK is a negative regulator of VEGFR3 signaling, and thereby its deletion leads to overactivation of VEGFR3 signaling, increased cell proliferation and aberrant lymphatic vasculature.
This is an interesting manuscript that sheds new light to the function of ILK and the role of integrin-RTK crosstalk during development and tissue repair in adults. The authors use multiple mouse models to provide a comprehensive view on the in vivo functions of ILK. The experiments are of high quality and the manuscript is well written.
A few issues should be addressed prior to publication:
1. In Fig. 1 N and 5G quantifications of pH3 staining as a function of field of view (Fig. 1N ) or total skin vasculature (Fig. 5G ) is shown. As the surface area of the vasculature is clearly increased in the mutants, this is not an appropriate way to quantify proliferation. The authors should quantify pH3-positive nuclei per total lymphatic vasculature nuclei to really demonstrate that proliferation is truly increased and to exclude that the increase pH3 staining is not just a proportional increase to the amount of cells. We now provide a blinded quantification of the number of pH3-positive LEC nuclei relative to the total number of LECs at E13.0, a stage when the number of LECs per jugular lymph sac / primordial thoracic duct (jls/pTD) is not yet different between ILK K.O. and control (Appendix Fig. S4 ). The data show that even when normalised to total LEC number and analysed in a blinded manner, more LEC proliferation is observed in ILK K.O. embryos compared to control littermates. We could not perform this additional analysis on the skin vasculature though, as the skin was stained in wholemount and thus cell nuclei were difficult to count. However, even though the referee did not request this experiment, we also quantified another cell proliferation marker besides pH3 in a blinded manner. We now show that the number of Ki67/Prox1-double positive cell nuclei is higher in ILK K.O. jls/pTD compared to control jls/pTD (Fig. EV1 ).
2. In fig. 3 the authors demonstrate using PLA that the beta1-VEGFR3 interaction is altered upon ILK deletion. It is surprising that most of the PLA signal comes from the cytoplasm inside the cell and not from the basal plasma membrane where beta1 and VEGFR would be available for ligand binding for this interaction to be able to regulate signaling. Regular IF with enough resolution to confortably identify the cell surface should be used to demonstrate where these tow receptors are localized and where this interaction occurs. We stained non-permeabilised tissue sections of the jls/pTD for the extracellular part of VEGFR3 (revised Fig. 3 ). This staining was followed by staining for the intracellular part of β1 integrin in the presence of detergent. The data show that the IgG control antibodies precipitated virtually no HA-tagged β1 integrin and less ILK protein compared to the anti-HA antibodies. As regards the protein amount used for immunoprecipitation in Fig. 8F , G, we plated the same number of cells (at the same passage) on stretch chambers that only differed in whether the chambers were stretched. After lysing the stretched and unstretched cells, a BCA assay was performed to take care that the same amount of proteins is used for precipitations with anti-HA antibodies. As all cells (i.e., stretched and unstretched LECs) expressed HA-tagged β1 integrin, the intensity of each ILK protein band was normalised to the corresponding HA-tagged β1 integrin band within each IP sample (Fig. 8F, G) . Fig 9 is interesting but at this point there is not much evidence to support it and especially the role of the actin cytoskeleton that has a prominent role in the model has not been tested at all. The authors should address (perhaps using immunofluorescence), whether ILK is truly displaced, along with the actin cytoskeleton, from beta1 integrin adhesion sites upon mechanical stretch. In addition, they should test if the actin cytoskeleton is disorganized in ILKdeficient LECs and whether actin disrupting drugs would be sufficient to increase VEGR3 phosphorylation and LEC Unfortunately, in our hands, antibodies against ILK did not work for immunostainings. Since the antibodies worked well in Western blots, we used Co-IP experiments to show that mechanical stretching results in a dissociation of ILK from HA-tagged β1 integrin (Fig. 8F, G) , which is consistent with the model proposed in Fig. 9 . We recognised that a knockdown of ILK affects the F-actin cytoskeleton in human LECs, which is consistent with published reports from multiple different laboratories (e. However, as our results on VEGFR3 activation in human LECs varied depending on the concentration of actin disrupting drugs, such as Latrunculin B and Cytochalasin D, and the duration of treatment, we applied genetic manipulations. More specifically, we used three different siRNAs for ILK and provided genetic evidence that ILK expression is required for normal expression of α-parvin (Fig. EV5A-C) , which is a key F-actin binding protein of the IPP/integrin complex (reviewed by Legate et al., Nat. Rev. Mol. Cell Biol. 2006). By contrast, silencing PARVA, the gene for α-parvin, by using three different siRNAs did not substantially reduce expression of ILK in human LECs (Fig. EV5D-F) . The data therefore support our model presented in Fig. 9 by showing that ILK is upstream of α-parvin. . Notably, these mouse embryos partially phenocopied the knockout of Ilk in that the number of LECs and number of proliferating LECs per jls/pTD section were higher compared to control littermates (Fig. EV2) . The levels of VEGFR3 tyrosine phosphorylation were also (but not significantly) higher in the LECs from Parva-deficient embryos compared to control littermates (Appendix Fig. S8 ). We believe that the sum of these data (in combination with published literature on ILK) strongly supports our model presented in Fig. 9 .
The model proposed in

Referee #2:
This is a very high quality manuscript with excellent data, novel findings and clear presentation. The data compellingly support the conclusions of the manuscript. I only have two points to raise which are listed below.
1. In Figure 2 the Authors contrast results for VEGFR-3 and VEGFR-2 in jls/pTD. The results for PLA sites are expressed as percentages so it is difficult to appreciate the relative abundance of VEGFR-3 versus VEGFR-2. Given this experiment pertains to lymphatic endothelium, one might expect a higher abundance of VEGFR-3 than VEGFR-2. If that was so, was there enough VEGFR-2 for a meaningful analysis of PLA sites to be done? In the revised manuscript, we show that VEGFR2 staining intensity in the jls/pTD is strong enough to obtain meaningful results regarding its tyrosine phosphorylation in both ILK K.O. and control embryos (Appendix Fig. S7 ). Now, we also provide a quantification of total PLA dots per jls/pTD section to show that only tyrosine phosphorylation of VEGFR3 (but not VEGFR2) is substantially increased upon Ilk deletion (Fig. 2K) . Figure 8F are not convincing. The images only show a small amount of each blot so it is hard to assess the specificity of the results. The Authors should provide the journal with images of the entire blots to demonstrate specificity. We now provide supplementary information (Source data) to show all stained parts of the Western blots in their entire lengths.
The Western blots in
Referee #3:
Comments for Editors
Comments for the authors
Major comments: 1. In Figure1, the authors claim that ILK prevents lymphatic overgrowth during mouse development as evidenced by the phenotype of endothelial ILK-knockout (KO) embryo, a model established by using the Flk1-Cre mice, which had enlarged jugular lymph sac (JLS) and increased lymphatic endothelial cell (LEC) number. The major concern is that Flk1-Cre mice might affect the developing blood vessels of major organs such as brain, heart, and kidney, all of which can be a cause of edema other than the defects in lymphatic morphogenesis. The authors used Prox1-CreERT2 mice to specifically delete ILK in adult period. It is questionable why the authors did not use this Cre line for the developmental analysis in Figures 1-4 . Furthermore, the authors showed gross embryonic day 13.5 image with head bleeding in Figure 1E by endothelial ILK-KO, which is quite an unusual phenotype to occur by lymphatic-specific defect. This should be explained and discussed in more detail. Prior work in our laboratory used the Flk1-Cre mouse to study the role of β1 integrin in lymphatic vascular growth (Planas-Paz et al., EMBO J 2012); in order to compare the results from this study to prior work, we chose to use consistent mouse genetic knockout lines. We acknowledge that Flk1-Cre also drives deletion in blood vascular endothelium (and also in hematopoietic cells), and thus followed this referee's advice and used Prox1-Cre ERT2 mice to delete Ilk in the embryonic lymphatic vasculature. Consistent with a regulatory role of ILK in LEC proliferation and VEGFR3 signalling, we show that Prox1-driven depletion of ILK from LECs (that we called "Induced ILK K.O.") resulted in enhanced LEC proliferation and more VEGFR3 tyrosine phosphorylation compared to the tamoxifen-treated controls (Fig. EV3 and EV4 ).
2. The authors showed the increase in Ilk gene expression during mouse embryonic development (E12.0-E13.5) and their inverse correlation with pHH3+ LECs and VEGFR3/phospho-tyrosine sites in Figure EV2 . However, staining and expression patterns of ILK 'protein' in mouse embryo samples should be provided to see if they are expressed in lymphatic vessels and in blood vessels during development in addition to adult lymphatics which the authors have already described (ear skin and post-MI heart lymphatics). We tested several antibodies against ILK on sections through embryonic and adult mouse tissues as well as on human LECs, but in our hands, no specific staining could be obtained. However, we obtained a good and specific detection of ILK in Western blots. Therefore, we now provide Western blot data for LECs sorted from mouse E13.5 jugular regions via MACS (Appendix Fig. S6D ). Since we isolated LECs from a total of 28x E13.5 mouse embryos to obtain sufficient protein to detect Prox1 and ILK in Western blots, we did not pursue to isolate LECs from even smaller E12.0 or E12.5 embryos. Our data on E13.5 embryos show that LECs express the ILK protein when its mRNA is high, while VEGFR3 tyrosine phosphorylation and LEC proliferation are low. We also show that the ILK protein is expressed in LECs sorted from adult mouse hearts (Appendix Fig.  S6D ). Given that we could show ILK protein expression in sorted mouse embryonic LECs and adult heart LECs and that we could also reproduce our key embryonic data on ILK by using a LECspecific Prox1-Cre ERT2 driven deletion of Ilk, our data strongly argue for cell autonomous effects of ILK in mouse LECs. Finally, we also provide Western blots to reveal a strong and specific ILK protein expression in human LECs (Appendix Fig. S11B and Fig. EV5A, D) that also argue for a cell autonomous role of ILK in VEGFR3 phosphorylation and LEC proliferation (Fig. 7) . Please note that we do not exclude that ILK plays any role in other tissues, since it has been previously shown to be expressed in almost all cells (Sakai et al., Genes & Development 2003).
3. In Figure 5 , the authors claim that lymphatic ILK-KO in adult period increases lymphatic vessel density (LVD) in mouse ear skin. The authors should present a lower magnification image to show that the LVD is indeed increased in ILK-KO. Furthermore, lymphatic vessel morphology in control ear skin ( Figure 5B ) seems quite strange because VEGFR3 expression seems heterogeneous compared to ILK-KO; we suggest evaluating images of similar areas of ear skin between control and ILK-KO. In addition, in Figure 5E -F, when normalized by vessel 'diameter', pHH3+ LECs seem similar between control and ILK-KO; this should also be compared in similar areas of ear skin. We now show a tile scan of the entire ear skin derived from adult control versus adult ILK K.O. mice (revised Fig. 5A, B) . In addition, we now show a lower magnification of pH3 and VEGFR3 staining of mouse ears using a 10x objective (revised Fig. 5E, F) . Even though at this low magnification, the pH3-positive LEC nuclei are difficult to see, the new images demonstrate that similar ear skin areas were compared in our analyses. Our data provide evidence that in the ear skin, the lymphatic vessel area is larger and LEC proliferation is higher upon ILK depletion compared to tamoxifen-injected control mice.
Minor comments: 1. The authors claim that adult ILK-KO in mouse heart does not bring any changes in LVD in physiologic conditions, but LVD is increased after MI. However, ILK is known to be expressed in cardiomyocytes and regulate cardiac function as the authors mentioned, but its role is unknown in the cardiac lymphatics. The authors should also check the protein expression patterns of ILK in cardiac lymphatics. Furthermore, post-MI hearts in ILK-KO mice seem to have not only increased LVD but also increased blood vessel density in Figure 6F -6G, which suggests that ILK-KO itself might not be the contributing factor of increased LVD in post-MI hearts. As mentioned before, we isolated LECs from dissociated adult mouse hearts using MACS and observed that the ILK protein is expressed in cardiac LECs (Appendix Fig. S6D ). In addition, we quantified blood vascular density, i.e., endothelial cells stained with CD31. We included these data in the revised Fig. 6 , which shows that the blood vessel density is unchanged in the adult heart (Fig.  6D ), yet decreased in the post-MI heart (Fig. 6H). 2. The authors claim that ILK does not regulate β1 integrin activation in LECs by providing activated β1 integrin staining in Figure 3A -D. However, it is hard to reach such conclusion with this data alone. As shown in Figure EV2 , changes in transcript levels of β1 integrin according to ILK might be necessary to support the authors' claim. In addition, β1 integrin is quite non-specific and binds to any receptors. Is there any specific subtype of alpha family integrin as a partner for VEGFR3 and ILK interaction in LECs? We included a co-staining of total β1 integrin with an established antibody (e.g. Turlo et al., Dev Biol 2012; Planas-Paz et al., EMBO J 2012, Lorenz et al., Nature 2018) recognising both activated and non-activated β1 integrin, and quantified the staining intensity of total β1 integrin in LECs (Appendix Fig. S9A-D, I ). We observed no change in the staining intensity of total β1 integrin in the LECs of ILK K.O. versus control jls/pTD (Appendix Fig. S9I ). With regard to the α subunit, Zhang et al. (J Cell Physiol 2005) identified α5 integrin as the subunit that combines with β1 integrin in LECs to influence their VEGFR3 activity and growth. We refer to this reference in the introduction.
3. In Figure 4 , the authors claim that LEC proliferation by ILK-KO is rescued by heterozygous deletion of β1 integrin in endothelial cells during mouse development by analyzing parameters such as pHH3 and p-Tyr PLA staining. However, the gross phenotype in Figure 4C looks worse than the ILK-KO phenotype alone in terms of overall embryo size at E13.5 and hemorrhage, which should be discussed by the authors. In the revised manuscript, we included more information about the ILK K.O. and genetic rescue in Appendix Fig. S1A and Appendix Fig. S1C , respectively. We also replaced Fig. 4C with a more representative image. Our data show that survival of ILK K.O. mouse embryos with an additional heterozygous deletion of Itgb1 is worse than the survival of the embryos with an ILK K.O. alone (possibly due to some genetic deletion in hematopoietic cells that are required for embryonic survival). However, relevant to this manuscript, our data show that the vascular phenotype is rescued, that is, fewer genetically rescued embryos have oedema and fewer have haemorrhages compared to embryos with an ILK K.O. alone. 4. LEC numbers seem similar between the control and ILK-KO but the Lyve-1 staining pattern seems different between the control and ILK-KO groups because it seems decreased in the ILK-KO group ( Figure 2C as well as in Figures 3A and 3C) , which is inconsistent with the authors' claim. Low magnification images in Fig. 1D , H and quantification of LEC numbers in Fig. 1M provide compelling evidence that the jls/pTDs are significantly larger and that more LECs per jls/pTD are present in embryos with an Ilk deletion (reproduced with Prox1 staining in Appendix Fig. S3 ). To investigate whether Lyve1 staining is changed, we quantified the Lyve1 staining intensity per LEC in ILK K.O. versus control littermates, but did not observe any difference.
5. According to the authors' claim, ILK-KO consistently increases LVD, even 3 weeks after Cre induction. It is questionable whether p-VEGFR3 remains much higher than the control even 3 weeks after the Cre induction in Figure 5H . Have the authors observed changes in LVD for longer than 3 weeks after Cre induction? In Fig. 6E-H , we show that the lymphatic vessel density (LVD) is higher in post-MI hearts of adult ILK K.O. mice compared to control mice, even when tamoxifen was injected to delete Ilk more than six weeks before analysis of the LVD. In addition, there are also more lymphatic vessels protruding into the cornea six weeks after the last tamoxifen injection (Fig. 5L-N In general, we did not observe any obvious lymphatic oedema in adult mice. However, we observed a non-significant increase (+36%) in the lymphatic vessel density (LVD) in lymph nodes of adult mice 10 days after the last tamoxifen injection. We also quantified the size of the dermal lymphatic vessels in E14.5 mouse embryos and found a non-significant increase in lymph vessel area normalized to the number of lymph vessels in ILK K.O. versus control embryos (in an experiment with n = 3 embryos, Appendix Fig. S2 ). Since the ILK K.O. phenotype gets more complicated during later embryonic development, we focused on the initial lymphatic vascular phenotype in ILK K.O. embryos.
7. Authors show that mechanical stress reduces ILK and increases the interaction between the β1 integrin and VEGFR3 by in vitro studies in Figure 8 . However, in the cornea model the authors showed in Figures 5I-J , what is the possible upstream that depletes ILK in the aspect of pathologic settings, because the authors did not manipulate any mechanical stimuli in the adult cornea with or without ILK. There is a variety of mechanical stimuli to which the cornea is exposed (reviewed in Masterton and Ahearne, Exp Eye Res 2018). We can speculate on the role of ILK in the aspect of both physiologic and pathologic settings in the cornea. For example, an increased intraocular pressure that can cause corneal oedema (e.g., see Ytteborg and Dohlman, Arch Ophthalmol 1965) could change the mechanical properties of the cornea, thus inducing a temporary release of ILK from β1 integrin, enabling the latter to interact with VEGFR3 and induce its signalling.
8. To convincingly demonstrate the differences in JLS by ILK-KO, the authors should describe which region of embryos, i.e. spanning from neck to heart, were sectioned for analysis for Figure 1 in Material and Methods section. We now included a more detailed description in the Methods part entitled 'Immunohistochemistry of Embryonic Sections'. Notably, the entire jls/pTDs were sectioned from the top -beginning in the neck region -to the bottom -where the heart begins -and most of the jls/pTDs were imaged and quantified for proliferation analyses. To determine the number of LECs per jls/pTD section, we chose sections from the central part of the jls/pTDs where they were fully lumenized. For the revision, we additionally quantified the total number of LECs in the entire jls/pTDs (Appendix Fig.  S3F ), and found a significantly higher LEC number in ILK K.O. versus control embryos. Thus, our data indicate that ILK K.O. embryos have larger jls/pTDs in both width and length (Appendix Fig.  S3E, F) .
9. It would be better to show the number of LECs with Prox1 staining rather than Lyve1 and nuclei staining in Figures 1I-L , because it is hard to identify Lyve1 and nuclei double-positive LECs, and the number of LECs look similar between control and ILK-KO by the image presented in Figures  1I-L . In Figure 6 , are LYVE1+ cells are lymphatics or macrophages? Authors should consider double Prox1+/LYVE1+ cells as definitive LECs. As mentioned before, we sectioned the entire jls/pTD from ILK K.O. versus control littermates and stained the sections for Prox1 (Appendix Fig. S3) . The data show that significantly more Prox1-positive LECs are present per jls/pTD section and even more Prox1-positive LECs are counted in the sum of all analysed jls/pTD sections when Ilk is deleted from mouse embryos (Appendix Fig.  S3E, F) . To show that it is the LECs (rather than the macrophages) that increase in number in ILK K.O. hearts compared to control hearts upon myocardial infarction (MI), we quantified areas that were double positive for Lyve1 and CD68 (a marker for macrophages). The quantification revealed that macrophages constitute only around 1% of the total Lyve1-positive area, and that there is no difference in this CD68/Lyve1-double positive area between ILK K.O. and control post-MI hearts (Appendix Fig. S10) . Thus, there are definitely more LECs found in post-MI hearts upon Ilk deletion (Fig 6E-G) .
10. As authors used Flk1-Cre mice, they should also describe whether blood endothelial cell number and proliferation are affected in Figure 1I Thank you for submitting a revised version of your manuscript. It has now been seen by both of the original referees whose comments are shown below.
As you will see, referee #3 finds that all criticisms have been sufficiently addressed and recommend the manuscript for publication. Referee #1, on the other hand, has remaining concerns regarding the control of the IP experiment in (now) Figure 8F . I find this concern reasonable, I therefore encourage you to address it either by submitting another piece of data you may have at hand containing the aforementioned control that is run together with the other samples. Alternatively, you could rephrase the text and maybe tone down the conclusion of the panel since the same conclusion is also supported by the PLA experiments. We can discuss this further if you wish.
In addition, before I can officially accept the manuscript, there are a few editorial issues concerning text and figures that I need you to address.
REFEREE REPORTS:
Referee #1:
The authors have addressed most of my concerns and the manuscript has improved. They have, however, not properly addressed my concern about proper controls for the immunoprecipitation experiment. It is standard in the field to include a IgG control in an IP and run it in the same gel as the actual experiment, only then it serves as a proper control to assess the extent of unspecific binding. Now the control has been run separately and is buried in the supplementary figure 12.
Further, this control is of poor quality as the ILK blot is so underexposed that the ILK bands are not visible in the HA blot either. Finally, a input lysate needs to be included to exclude that ILK levels are not decreased upon stretch (without altering and irrespective of the total protein content), because such a decrease could directly explain reduced co-precipitation without affecting the interaction itself. So the argument of the BCA assay and equal amounts of protein used is irrelevant here.
The authors adequately addressed my comments. It is ready to be published into EMBO J.
2nd Revision -authors' response 5th Nov 2018
Point-by-point reply to the referees' comments:
We would like to thank referee #3 for his positive feedback and referee #1 for her/his additional advice concerning the immunoprecipitation experiment.
Referee #1:
Further, this control is of poor quality as the ILK blot is so underexposed that the ILK bands are not visible in the HA blot either. Finally, a input lysate needs to be included to exclude that ILK levels are not decreased upon stretch (without altering and irrespective of the total protein content), because such a decrease could directly explain reduced co-precipitation without affecting the interaction itself. So the argument of the BCA assay and equal amounts of protein used is irrelevant here. We agree that it is a stronger experiment to perform the IgG and protein control experiments on the cell lysates used for co-IP experiments and place all samples on the same gel. However, we believe that splitting n = 9 lysates, applying different experiments to these split lysates, and then applying the 27 samples onto one gel along with a protein marker can also affect the experimental outcome. More notably, for n = 1 biological sample of ILK co-precipitated with HA-tagged β1 integrin, LEC lysates need to be pooled from n = 3 stretch chambers. This is due to (i) the small surface area of the stretch chambers, (ii) the low numbers of transfected LECs attaching to these chambers, and (iii) the small amount of ILK co-precipitated with HA-tagged β1 integrin (in the absence of protein crosslinking). We now mention the latter in the corresponding text to tone down the strength of this experiment instead of performing the suggested experiment that is technically difficult to perform given the large number of stretch chambers required to obtain sufficient cell lysates. However, it is noteworthy that the amount of ILK was normalized to HA-tagged β1 integrin in the same lysates run in the same gel, providing an appropriate normalization (see Fig. 8G ), and that the analysis of cell lysates from stretched versus unstretched LECs did not provide any evidence for a substantial reduction of ILK protein in LECs upon mechanical stretching (see Appendix Fig S12D, E) .
Referee #3:
3rd Editorial Decision 7th Nov 2018
Thank you for submitting the revised version of your manuscript. I have now looked at everything and all looks fine. Therefore I am very pleased to accept your manuscript for publication in The EMBO Journal.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND #
No statistical method was used to estimate sample size, but sample size was chosen based on experience from previous experiments. Experiments were generally conducted with at least n = 3 biological samples.
No statistical method was used to estimate sample size, but sample size was chosen based on experience from previous experiments. Experiments were generally conducted with at least n = 3 biological samples. Too high numbers were avoided for technical reasons and/or in order to keep the number of animals used in experiments as low as possible.
Significant outliers were detected by ESD method (Grubbs' test) and excluded from analysis for n ≥ 4. In addition, adult mice with morphological abnormalities were excluded from the analysis.
No explicit randomization method was performed.
N/A , since treatments were identical for all experimental groups.
Investigators were blinded during some experiments in the way that imaging and/or quantifications were performed in a blinded manner.
Investigators were blinded during some experiments in the way that imaging and/or quantifications were performed in a blinded manner. In addition, isolation of genetically modified embryos was blinded, since the genotype was not known during isolation.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
Please fill out these boxes # (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C--Reagents B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects. This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
